Kelly Renee Reveles, Pharm.D., Ph.D., BCPS

Ambulatory Care Practice & Research Network Paper of the Year
American College of Clinical Pharmacy
October 2019

Top 10 Faculty for PharmD Student Academic/Professional Impact
The University of Texas at Austin College of Pharmacy
September 2019

Distinguished Young Alumnus
The University of Texas at Austin College of Pharmacy
September 2019

Preceptor Excellence Award for Interprofessional Education
San Antonio Regional Internship Program
The University of Texas at Austin College of Pharmacy
July 2019

Introductory Pharmacy Practice Experience (IPPE) Preceptor Excellence Award
The University of Texas at Austin College of Pharmacy
April 2018

NIH/National Institute of Allergy and Infectious Diseases Loan Repayment Award, Clinical Research (Competitive Renewal)
1 L30 TR000604-01
“Molecular and clinical epidemiology of Clostridium difficile infection in South Texas“
August 2017

NIH/National Center for Advancing Translational Science Loan Repayment Award, Clinical Research (Competitive Renewal)
1 L30 TR000604-01
“Recurrence risk prediction of Clostridium difficile infections”
July 2014

Participant, NIH/NCATS (National Center for Advancing Translational Science) Loan Repayment Award, Clinical Research
1 L30 TR000604-01
“Prevention of catheter-related bloodstream infections”
September 2013

Yeh and Salmon (Co-PIs)                                                                 09/01/18-08/31/20
NIH/National Institute on Aging Exploratory Research Grant Award (R21)
Biology of aging oral health and anti-aging intervention in a non-human primate model
Goals: 1) establish the changes in oral health (including oral microbiome) and relationship to general physiological function in aging marmosets and 2) test whether inhibition of mTOR improves these outcomes
Role: Consultant

Lee (PI)                                                                                            06/26/18-06/01/20
Merck & Co., Inc.
Molecular epidemiology of carbapenem-resistant Enterobacteriaceae in South Texas
Goals: 1) describe the molecular and clinical epidemiology of carbapenem-resistant Enterobacteriaceae in South Texas, 2) assess the activity of imipenem-relebactam against these isolates, and 3) identify genes associated with imipenem-relebactam resistance
Role: Co-investigator

Musi (PI) 1P30AG044271-01A1                                                    06/15/15-04/30/20
NIH/National Institute on Aging
San Antonio Claude D. Pepper Older Americans Independence Center (OAIC)
Goals: The primary objective of the center is to provide investigators with the scientific infrastructure and services that are requisite to translate innovative interventions that target the aging process and age-related diseases into humans.

Yeh (PI)                                                                                          06/01/18-05/31/19
OAIC Pilot Grant Program
Establishment of a novel marmoset model for elucidating the effect of aging on oral health
Goals: determine the effect of aging on oral health (including oral microbiome) in marmosets
Role: Consultant

Ross (PI)                                                                                       05/01/17-04/30/18
OAIC Pilot Grant Program
Marmoset gut microbiome and aging
Goals: 1) compare gut microbiota composition between young and old marmosets and 2) determine whether the marmoset gut microbiome can be safely altered with fecal microbiota
transplantation.

Reveles (PI)                                                                                  06/15/15-05/01/17
OAIC Career Development (KL2) Program
Comparison of gut microbiota composition and inflammation of elderly proton pump inhibitor (PPI)-users and non-users
Goals: This project will compare the fecal microbiota composition, inflammatory markers, and IGF-1 levels in chronic PPI users compared to non-users.
Role: Principal investigator

Reveles (PI)                                                                                  05/01/17-04/30/18
ReACH Pilot Grant Program
The microbiome as a potential mediator of diabetes health disparities
Goal: determine if the gut microbiome composition among Mexican Americans is associated with diabetes independent of factors associated with health disparities in this population
Role: Principal investigator

1. Carlson TJ, Endres BT, Pham JL, Gonzales-Luna AJ, Alnezary FS, Nebo K, Miranda J, Begum K, Alam MJ, Reveles KR, Garey KW. Eosinopenia and binary toxin increases mortality in hospitalized patients with Clostridioides difficile infection. Open Forum Infectious Diseases (in press).
2. Evoy KE, Leonard CE, Covvey JR, Ochs L, Peckham AM, Soprano S, Reveles KR. The prevalence of substance use disorder counseling among patients prescribed opioids: an analysis of the national ambulatory medical care survey. Substance Abuse: Research and Treatment (in press).
3. Evoy KE, Groff L, Hill L, Godinez W, Gandhi R, Reveles KR. Impact of naloxone academic detailing at community pharmacies in Texas. Journal of the American Pharmacists Association Oct 2019 [Epub ahead of print].
4. Mootz ML, Britt RS, Mootz AA, Lee GC, Reveles KR, Evoy KE, Teng C, Frei CR. Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hospital Practice Oct 2019 [Epub ahead of print].
5. Kitten AK, Kamath M, Ryan L, Reveles KR. National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015. PLoS One Aug 2019;14(8):e0221174.
6. Reveles KR, Dotson KM, Gonzales-Luna A, Surati D, Endres BT, Alam MJ, Garey KW. Clostridioides (formerly Clostridium) difficile infection during hospitalization increases the likelihood of non-home patient discharge. Clinical Infectious Diseases May 2019;68(11):1887-1893.
7. Teng C, Reveles KR, Obodozie-Ofoegbu O, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. International Journal of Medical Sciences May 2019;16(5):630-635.
8. Argamany JR, Lee GC, Duhon BD, Zeidan AR, Young EH, Reveles KR. A possible association between statin use and improved Clostridioides difficile infection mortality in veterans. PLoS One May 2019;14(5):e0217423.
9. Reveles KR, Patel S, Forney LJ, Ross CN. Age-related changes in the marmoset gut microbiome. American Journal of Primatology Feb 2019;81(2):e22960.
10. Bustillos H, Leer K, Kitten AK, Reveles KR. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. PLoS One Nov 2018;13(11):e0208461.
11. Evoy KE, Hill LG, Groff L, Mazin L, Carlson C, Reveles KR. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. Journal of the American Medical Association Nov 2018;320(18):1934-1937.
12. Reveles KR, Cosimi RA, Ryan CN, Chan LS, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut Jul 2018;67(7):1369-1370.
13. Reveles KR, Mortensen EM, Koeller JM, Lawson KA, Pugh MV, Rumbellow SA, Argamany JR, Frei CR. Derivation and validation of a Clostridium difficile infection recurrence prediction rule in a national cohort of veterans. Pharmacotherapy 2018 (Epub ahead of print).
14. Reveles KR, Lawson KA, Mortensen EM, Pugh MV, Koeller JM, Argamany JR, Frei CR. National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. PLoS One 2017;12(12):e0189227.
15. Reveles KR, Pugh MV, Lawson KA, Mortensen EM, Koeller JM, Argamany JR, Frei CR. Shift to community-onset Clostridium difficile infection in the national Veterans Health Administration, 2003 to 2014. American Journal of Infection Control (Epub ahead of print).
16. Reveles KR, Backo JL, Corvino FA, Zivkovic M, Broderick KC. Fidaxomicin versus vancomycin as first-line treatment for Clostridium difficile-associated diarrhea (CDAD) in specific patient populations: a pharmacoeconomic evaluation. Pharmacotherapy 2017;37(12):1489-1497.
17. Reveles KR, Cosimi RA, Ryan CN, Chan LS, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut Oct 2017 (Epub ahead of print).
18. Britt BS, Evoy KE, Lee GC, Reveles KR, Sorensen KM, Jones X, Bollinger M, Frei CR. Early use of ceftaroline fosamil use in the United States Veterans Health Care System. Drugs Aug 2017;77(12):1345-1351.
19. Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes of among cancer patients diagnosed with Clostridium difficile infections in the United States community hospitals. BMC Infectious Diseases Jun 2017;17(1):448.
20. Arizpe A, Reveles KR, Aitken SL. Regional variation in antibiotic prescribing among Medicare Part D enrollees, 2013. BMC Infectious Diseases Dec 2016;16(1):744.
21. Pechal A, Lin K, Allen SM, Reveles KR. National age group trends in Clostridium difficile infection incidence and health outcomes in United States community hospitals. BMC Infectious Diseases Nov 2016;16(1):682.
22. Reveles KR, Duhon BD, Moore RJ, Hand EO, Howell CK. Epidemiology of methicillin-resistant Staphylococcus aureus diabetic foot infections in a large academic hospital: implications for antimicrobial stewardship. PLoS One Aug 2016;11(8):e0161658.
23. Argamany JR, Delgado A, Reveles KR. Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010. BMC Infectious Diseases Aug 2016;16(1):454.

Dr. Reveles’ research on Clostridium difficile infections has recently been highlighted by several prominent media outlets, including The New York Times. Please follow the links below to view several news articles.

Reveles traces rate of hospital infections
Featured article on The University of Texas at Austin College of Pharmacy Home Page

Hospital infections with C. difficile level off
The New York Times

Infamous diarrhea‐causing infections nearly double in U.S. hospitals
Popular Science

Rates of antibiotic‐resistant superbug double over last decade
Aljazeera America

'Deadly diarrhea’ rates nearly doubled in 10 years: study
Association for Professionals in Infection Control and Epidemiology